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Psychoactive drug advertising: 
analysis of scientifi c 
information
ABSTRACT
OBJECTIVE: According to the World Health Organization, medicinal 
drug promotion should be reliable, accurate, truthful, informative, balanced, 
up-to-date and capable of substantiation. The objective of the present 
study was to review psychoactive drug advertisements to physicians as for 
information consistency with the related references and accessibility of the 
cited references.
METHODS: Data was collected in the city of Araraquara, Southeastern Brazil, 
in 2005. There were collected and reviewed 152 drug advertisements, a total 
of 304 references. References were requested directly from pharmaceutical 
companies’ customer services and searched in UNESP (Ibict, Athenas) and 
BIREME (SciELO, PubMed, free-access indexed journals) library network and 
CAPES journals. Advertisement statements were checked against references 
using content analysis.
RESULTS: Of all references cited in the advertisements studied, 66.7% 
were accessed. Of 639 promotional statements identifi ed, 346 (54%) were 
analyzed. The analysis showed that 67.7% of promotional statements in the 
advertisements were consistent with their references, while the remaining was 
either partially consistent or inconsistent. Of the material analyzed, an average 
2.5 (1–28) references was cited per advertisement. In the text body, there were 
identifi ed 639 pieces of information clearly associated with at least one cited 
reference (average 3.5 pieces of information per advertisement).
CONCLUSIONS: The study results evidenced difficult access to the 
references. Messages on effi cacy, safety and cost, among others, are not always 
supported by scientifi c studies. There is a need for regulation changes and 
effective monitoring of drug promotional materials.
DESCRIPTORS: Psychotropic Drugs. Drug Promoter. Products 
Publicity Control. Medication Systems, Hospital. National Drug Policy. 
Review [Publication Type].
INTRODUCTION
According to the World Health Organization (WHO), medicinal drug promo-
tion should be reliable, accurate, truthful, informative, balanced, up-to-date and 
capable of substantiation. Text and illustration contents should be consistent 
with scientifi c information.20
Non-ethical medicinal drug promotion is a major issue worldwide leading to 
irrational drug use, overprescription, self-medication and drug abuse.1,10,11 This 
is a more serious issue in developing countries such as Brazil. Studies have 
shown that promotional materials in medical journals in Brazil, the UK and 
the US have different contents,16 evidencing a double standard. The contents 
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of Brazilian advertisements are more subjective and 
incomplete compared to same drug materials advertised 
in the UK and US.3,15,16
Several studies1,7,12 and systematic reviews19,24 have 
described the effect of drug promotional materials on 
medical prescription. Above all, it is a more serious is-
sue for psychoactive drug advertising since it tends to be 
less informative than other medicinal drug promotional 
materials.4,9 In addition, these advertisements usually 
reinforce stereotypes of the association between gender 
and psychiatric conditions, showing a disproportion 
between women and men.14,15
Studies have also reported both misinformation and 
unbalanced information in drug promotion support-
ing their use: indication, presentation and dosage are 
often included and highlighted by larger font sizes and 
colorful text, whereas information restraining drug 
use, such as contraindications, warnings, precautions 
and adverse reactions, when available, are less evident 
and not as visible.15,17,22 However, these studies have 
not investigated the consistency between promotional 
claims and related cited references.
Few studies5,23 have addressed reliability, accuracy 
and truthfulness of information in drug promotional 
materials and their related cited references. Although it 
is a major issue and a requirement for complying with 
international recommendations,20 national drug regula-
tions (Ministerial Decree No. 3.916/98a), and current 
health law (Collegiate Board of Directors’ Resolution 
[RDC] No. 102/00b), there is no study to date address-
ing it in Brazil.
The purpose of the present study was to review 
psychoactive drug promotional materials targeted to 
physicians as for consistency of information with their 
related references and to assess accessibility of the 
cited references.
METHODS
The study sample consisted of psychoactive drug 
advertising materials to physicians provided by phar-
maceutical promoters in clinics, hospitals and health 
units. Data was collected in the city of Araraquara, 
Southeastern Brazil, in 2005.
Psychoactive drugs are prescription only medicines 
subject to special control and prescription retention. 
They can only be advertised to prescribers and dis-
pensers (RDC 102/00b, Art. 5a; Art. 13 and  HSS/MoH 
Administrative Rule No. 344/98c - Art. 12, item II; 
a Brasil. Portaria n° 3.916, de 30 de outubro de 1998. Aprova a Política Nacional de Medicamentos. Diário Ofi cial da União. 10 nov 1998.
b Brasil. Resolução RDC nº 102, de 30 de novembro de 2000. Aprova o Regulamento sobre propagandas, mensagens publicitárias e 
promocionais e outras práticas cujo objeto seja a divulgação, promoção ou comercialização de medicamentos de produção nacional ou 
importados, quaisquer que sejam as formas e meios de sua veiculação, incluindo as transmitidas no decorrer da programação normal das 
emissoras de rádio e televisão. Diário ofi cial da União. 1 dez 2000.
Art. 16) through promotional materials both delivered 
at health settings, and published in medical journals 
and books.
Pharmaceutical companies disseminate the same drug 
advertising materials nationwide. Thus, materials 
collected in the city of Araraquara can be deemed 
representative of psychoactive drug advertisements 
distributed to prescribers nationwide.
For data collection, physicians in hospitals, clinics and 
health units were contacted and the purpose of the study 
was explained. Those who agreed to participate were 
asked to voluntary retain all promotional materials for 
the team’s monthly collection.
No differences were seen in materials collected by site 
of collection since the same promoter of each pharma-
ceutical company used to visit the hospitals, clinics and 
health units and provide the same materials.
References were requested from physician and phar-
maceutical customer services (PPCS) through the 
number provided in the promotional materials. The 
references made available by PPCS were sent through 
mail and searched in UNESP (Ibict, Athenas), and BI-
REME libraries (Scielo, Pubmed, free-access indexed 
journals) and other on-line databases available, such 
as CAPES journals.
Reference information on access source (laboratory, 
library or unknown) and review status (reviewed, not 
reviewed and reason for no review) were entered into 
a database.
Content analysis of each reference obtained followed 
a guide developed based on a “fl oating reading” of 
promotional materials and their related references.2
The guide included the following:
Part I – Promotional material information: ID 
number, drug name, active component, class of 
therapeutic agent, pharmaceutical company name, 
PPCS number; cited references and number of 
references cited;
Part II – Review of cited references: type of re-
ference (published and indexed; published and 
non-indexed; unpublished article; book citation; 
pharmaceutical material; meeting presentation; 
association handbook; drug price guide); study 
category (meta-analysis; clinical trial; cohort stu-
dy; case-control study; editorial; review; survey; 
pharmacovigilance study), and consistency level 
(consistent; inconsistent or somewhat consistent 
with promotional claims).
•
•
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To prevent both subjective and differing interpreta-
tions, content analysis was conducted in duplicate by 
independent reviewers. In case of disagreement, a third 
reviewer would review the content. References were 
classifi ed according to study category and level of 
evidence and grade of recommendation.21
“Consistent” information was defi ned when promotion-
al claims were found in the cited reference; “somewhat 
consistent” information was defi ned when at least one 
claim or part of it was found in the cited reference; and 
“inconsistent” information was defi ned when promo-
tional claims were not found in the cited reference.
A database was electronically created in a fl ow chart 
to manage data collected.
The study was approved by UNIFESP Research Ethics 
Committee (Protocol No.176/06).
RESULTS
There were collected 167 different psychoactive drug 
advertising materials from 25 pharmaceutical compa-
nies. Most of them promoted antidepressive (41.9%) 
and anxiolytic drugs (24.5%). Fifteen promotional 
materials (from four pharmaceutical companies) were 
excluded as they did not provide any references.
Of 152 promotional materials reviewed, there were on 
average 2.5 (1–28) references cited per piece, making 
a total of 395 references. In their body, there were 
identifi ed 639 pieces of information that were clearly 
associated to at least one reference cited (mean 3.5 
pieces of information per material) (Figure).
Two pharmaceutical companies refused to provide 
the requested references. Although most companies 
claimed they did not have any references in their fi les, 
all those who agreed to collaborate said they will ask 
their headquarters or medical libraries to provide the 
requested references. It took three days to six months 
for companies to send them. Only one pharmaceutical 
company provided all references requested; the remain-
ing provided on average less than 50% of references 
cited and 107 (27%) references were directly obtained. 
The remaining 156 (39.5) references were accessed 
in libraries or other database referred in Methods. A 
total of 263 were obtained. The remaining references 
(132; 33.5%) were either not available in the compa-
nies’ headquarters or were not indexed in the database 
searched or unpublished (Table 1).
Most references were from studies published in indexed 
(291; 73.7%) or non-indexed (13; 3.3%) journals. Based 
on these 304 references, 260 studies were categorized 
through accessing their abstracts or entire content.
It was found that the majority of studies were clinical 
trials (N=116), meaning the highest level of evidence 
for therapeutic choice, followed by literature reviews 
(N=94), meaning the lowest level of evidence for 
therapeutic choice.21 In addition, there were found 
non-recommended studies such as pre-clinical studies 
(N=12), epidemiological surveys (N=6) and life quality 
assessment (N=1) (Table 2).
In regard to the level of consistency between promo-
tional claims and the related cited references, of 263 
references available (107 provided by pharmaceuti-
cal companies and 156 obtained from libraries and 
database), 346 claims were reviewed, 54% (346/639) 
of all claims identifi ed in the advertising materials 
collected.Table 1. Reasons for diffi cult access to cited references in 
psychoactive drug advertising materials. Araraquara, Sou-
theastern Brazil, 2005.
Reason N %
Articles not available or not 
provided by physician and 
pharmaceutical customer services
52 39.4
Drug price guides 22 16.7
Posters or presentations in 
scientifi c meetings
15 11.4
Books 10 7.6
References not cited in 
promotional materials
9 6.8
Unpublished pharmaceutical material 7 5.3
Unpublished sales report 5 3.8
Incomplete/inaccurate references 5 3.8
Articles written in French 3 2.3
Articles written in German 3 2.3
Brazilian government offi cial newspaper 1 0.6
Total 132 100
Table 2. Study categories of studies referenced in psycho-
active drug advertising materials. Araraquara, Southeastern 
Brazil, 2005.
Study category N %
Recommended
Clinical trial 116 44.6
Meta-analysis 8 3.1
Cohort study 8 3.1
Pharmacovigilance/case study 9 3.5
Reviews/Guides 94 36.1
Editorial 6 2.3
Not recommended
In vivo/in vitro pre-clinical study 12 4.6
Epidemiological survey 6 2.3
Quality of life assessment 1 0.4
Total 260 100
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In most claims reviewed (234; 67.7%), sentences or 
information were identifi ed in the cited reference. In 
15.6% (54), information was either incomplete or partly 
referred to the reference cited; and in 16.7% (58), no 
information was found in the reference cited.
Inconsistent or somewhat consistent content was due 
to missing or confl icting information found in the ref-
erenced studies, i.e., different drugs studied,  reviews 
of classes of therapeutic agents that did not provide 
specifi c information on the promoted drug, and different 
population studied, e.g., young adults when it claimed 
to be  “(…) safe for the elderly”. There were also found 
pieces of information including extrapolated results with 
increased level of statistical signifi cance; animal studies 
but claims were for humans; studies in patients with a 
single condition and claims about the drug effi cacy for 
patients with two or more conditions or even about the 
effi cacy in patients with co-morbidities (e.g., renal or 
liver failure) not investigated in the study (Table 3).
DISCUSSION
The present study showed diffi cult access to the refer-
ences cited in psychoactive drug advertising materials. 
Villanueva et al23 (2003) reported similar fi ndings after 
studying drug advertisements published in six Spanish 
newspapers. These authors did not have access to 18% 
of the cited references since they were monographs or 
unpublished data.23
Prescribers would fi nd even more diffi cult to have 
access to referenced information in drug promotional 
materials.
The present study also evidenced a need for changes in 
current health laws regarding drug promotion regula-
tions, banning citation of non-scientifi c based reference, 
such as drug price guides. Moreover, pharmaceutical 
companies should be required to make available full 
original studies in their websites and to cite in promo-
tional material studies designed at the recommended 
level of evidence for therapeutic choice, preferably 
published studies rather than posters and presentations 
given at scientifi c meetings.
Promotional materials often include incomplete, sum-
marized, inconsistent and different information than that 
in the referred studies,8 favorably supporting the thera-
peutic indication, drug effi cacy, safety and cost.18,19,24 
In contrast to previous studies that have reported low 
citation of references in advertising claims,15,17,22 in the 
present study, 91% of the materials reviewed had at least 
one reference. It can be noted that today pharmaceuti-
cal companies tend to provide references as marketing 
strategies of drug promotion.23
Pharmaceutical companies frequently draw on random-
ized clinical trial studies (44.6%) published in renowned 
indexed medical journals,5,23 especially intended for 
therapeutic choice.21 On the other hand, 36.1% of refer-
ences here studied were literature reviews, which are 
less recommended21 and in general promotional claims 
favorably supported drug use and omitted warnings 
and precautions to specifi c populations stressed in the 
reviews. Hence, unbalanced information is usually 
found in advertising claims.15,17,23
A good number of claims reviewed (67.7%) were 
consistent with the references because consistency was 
ascertained when the cited information was identifi ed 
regardless of any other considerations. RDC 102/00, 
Art. 15, establishes that “citations, tables or other il-
lustrations obtained from scientifi c publications and 
included in any advertisements or promotional materi-
Figure. Flow chart of cited references in psychoactive drug 
advertising materials reviewed. Araraquara, Southeastern 
Brazil, 2005.
15 advertising materials 
without any references 
from 4 pharmaceutical 
companies
167 psychoactive 
drug advertising materials 
from 25 pharmaceutical 
companies
152 advertising materials 
with references from 21 
pharmaceutical companies
395 references cited 
in the materials
639 pieces of information 
in the advertising materials 
with references
Table 3. Reasons for inconsistency or partial consistency be-
tween claims in psychoactive drug advertising materials and 
related references. Araraquara, Southeastern Brazil, 2005. 
Reason* N %
Missing information 87 62
Extrapolation regarding indication/
conditions/class of therapeutic agent 
12 12
Confl icting information or misinformation 14 10
Extrapolation to humans 8 5.6
Extrapolation of statistical data 7 5
Different population studied 6  4
Extrapolation regarding quality of life 2 1.4
Total 141 100
* Each claim may have more than one reason for 
inconsistency 
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als have to be accurately reproduced and cite the full 
reference”. Most citations were from literature reviews 
that contemplate pros and cons; pros were cited in the 
promotional materials but only positive results of clini-
cal trials were cited.
Studies have reported publication biases,6,13 i.e., studies 
with positive results supporting drug use are promptly 
published while unfavorable data require much more 
time to be published or even remain unpublished, which 
could explain the fact that most claims reviewed were 
consistent with the cited references. Also, because 
pharmaceutical companies fund clinical trials, the 
results are reported as part of their marketing strate-
gies23 so promotional claims tend to favorably support 
drug use.25
However, it is not known whether the same consistency 
would have been found if all 132 references not avail-
able, accounting for 293 claims that were not reviewed 
(46%), were accessed.
Inaccurate psychoactive drug advertising was found in 
32.3% of information reviewed. A similar fi nding was 
reported by Villanueva et al23 (2003) while studying 
promotional claims in antihypertensive drug advertise-
ments published in Spanish medical journals and related 
references (44.1%) and by Gómez-Garcia et  al5 (2005) 
while reviewing promotional materials provided to 
primary care physicians in Spain (44.5%).
Ziegler et al25 (1996) studied the accuracy of drug 
information provided to physicians by promoters and 
found that 11% were confl icting. In present study, 10% 
of inconsistent claims were due to misinformation or 
confl icting information.
The reasons for inconsistent or somewhat consistent 
information found in the present study were similar 
to those reported in other studies in Spain:5,23 missing 
information, other drugs studied, patients with condi-
tions not investigated in the studies, statistical differ-
ences were not signifi cant, extrapolation of indications 
and conditions and conclusions other than those claimed 
in the materials. According to RDC 102/00,a it is thus 
characterized misleading advertising due to information 
omission or misinformation.
Misinformation was often found in promotional materi-
als claiming effi cacy, safety and low costs. Low-cost 
claims were referenced to drug pride guides. Although 
cost-effective claims are usually seen in drug promo-
tion,18 there are required cost-effectiveness analyses 
comparing treatment costs rather than drug prices.
Health providers have to be more careful and apply 
their knowledge and better judgment while appraising 
promotional materials. Pharmaceutical companies are 
not concerned whether references are correctly cited, 
references are actually related to the drug promoted 
and comparisons are made between same classes of 
therapeutic agents. Health providers are unlikely to 
judiciously appraise advertising materials provided to 
them and thus become more prone to be infl uenced by 
promotional practices.19
In conclusion, the issue requires further discussion. It is 
proposed content analyses of drug advertising in under-
graduate studies, continuing education and permanent 
education programs to degree providers to encourage 
rational drug use and to prevent abusive prescription of 
psychoactive drugs and promotional practices to infl u-
ence health providers’ therapeutic choices.
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